CL2012001082A1 - Uso del acido (1r,2s)-1-[[(2s,4r)-4-[8-bromo-7-metoxi-2-[2-(2-metilpropanoilamino)-1,3-tiazol-4-il]quinolin-4-il]oxi-1-[(2s)-2-(ciclopentiloxicarbonilamino)-3,3-dimetilbutanoil]pirrolidin-2-carbonil]amino]-2-etenilciclopropan-1-carboxilico (bi201335), un interferon alfa y ribavirina para tratar la infeccion de hepatitis c viral. - Google Patents

Uso del acido (1r,2s)-1-[[(2s,4r)-4-[8-bromo-7-metoxi-2-[2-(2-metilpropanoilamino)-1,3-tiazol-4-il]quinolin-4-il]oxi-1-[(2s)-2-(ciclopentiloxicarbonilamino)-3,3-dimetilbutanoil]pirrolidin-2-carbonil]amino]-2-etenilciclopropan-1-carboxilico (bi201335), un interferon alfa y ribavirina para tratar la infeccion de hepatitis c viral.

Info

Publication number
CL2012001082A1
CL2012001082A1 CL2012001082A CL2012001082A CL2012001082A1 CL 2012001082 A1 CL2012001082 A1 CL 2012001082A1 CL 2012001082 A CL2012001082 A CL 2012001082A CL 2012001082 A CL2012001082 A CL 2012001082A CL 2012001082 A1 CL2012001082 A1 CL 2012001082A1
Authority
CL
Chile
Prior art keywords
ethenylcyclopropane
methylpropanoylamino
cyclopentyloxycarbonylamino
dimethylbutanoyl
ribavirin
Prior art date
Application number
CL2012001082A
Other languages
English (en)
Inventor
Carla Haefner
Gerhard Steinmann
Jarry O Stern
Chan-Loi Tong
Original Assignee
Boheringer Ingelheim Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43446722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001082(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boheringer Ingelheim Int Gmbh filed Critical Boheringer Ingelheim Int Gmbh
Publication of CL2012001082A1 publication Critical patent/CL2012001082A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso del ácido (1r,2s)-1-[[(2s,4r)-4-[8-bromo-7-metoxi-2-[2-(2-metilpropanoilamino)-1,3-tiazol-4-il]quinolin-4-il]oxi-1-[(2s)-2-(ciclopentiloxicarbonilamino)-3,3-dimetilbutanoil]pirrolidin-2-carbonil]amino]-2-etenilciclopropan-1-carboxílico(bi201335), un interferon alfa y ribavirina útil en la infección por hepatitis; composición farmacéutica.
CL2012001082A 2009-10-30 2012-04-26 Uso del acido (1r,2s)-1-[[(2s,4r)-4-[8-bromo-7-metoxi-2-[2-(2-metilpropanoilamino)-1,3-tiazol-4-il]quinolin-4-il]oxi-1-[(2s)-2-(ciclopentiloxicarbonilamino)-3,3-dimetilbutanoil]pirrolidin-2-carbonil]amino]-2-etenilciclopropan-1-carboxilico (bi201335), un interferon alfa y ribavirina para tratar la infeccion de hepatitis c viral. CL2012001082A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25651609P 2009-10-30 2009-10-30

Publications (1)

Publication Number Publication Date
CL2012001082A1 true CL2012001082A1 (es) 2012-08-17

Family

ID=43446722

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001082A CL2012001082A1 (es) 2009-10-30 2012-04-26 Uso del acido (1r,2s)-1-[[(2s,4r)-4-[8-bromo-7-metoxi-2-[2-(2-metilpropanoilamino)-1,3-tiazol-4-il]quinolin-4-il]oxi-1-[(2s)-2-(ciclopentiloxicarbonilamino)-3,3-dimetilbutanoil]pirrolidin-2-carbonil]amino]-2-etenilciclopropan-1-carboxilico (bi201335), un interferon alfa y ribavirina para tratar la infeccion de hepatitis c viral.

Country Status (17)

Country Link
US (1) US8822496B2 (es)
EP (1) EP2493470A1 (es)
JP (1) JP2013508425A (es)
KR (1) KR20120106942A (es)
CN (1) CN102596201A (es)
AU (1) AU2010313497B2 (es)
BR (1) BR112012010110A2 (es)
CA (1) CA2779244A1 (es)
CL (1) CL2012001082A1 (es)
EA (1) EA201200650A1 (es)
IL (1) IL218279A0 (es)
MX (1) MX2012004971A (es)
NZ (1) NZ598465A (es)
PH (1) PH12012500827A1 (es)
TW (1) TW201138773A (es)
WO (1) WO2011053617A1 (es)
ZA (1) ZA201201427B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2737376A1 (en) * 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013137869A1 (en) * 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
JP2015512900A (ja) * 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4247479A (en) 1976-12-03 1981-01-27 Hoechst Aktiengesellschaft Process for the manufacture of aromatic amines from α, β-unsaturated cycloaliphatic ketoximes
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
DE69632062T2 (de) 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
DK1087778T3 (da) 1998-06-08 2005-12-19 Hoffmann La Roche Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
AU759480B2 (en) 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6824768B2 (en) 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
KR20030027016A (ko) 2000-08-09 2003-04-03 에프. 호프만-라 로슈 아게 항-염증제로서의 퀴놀린 유도체
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
WO2004089974A1 (en) 2003-04-10 2004-10-21 Boehringer Ingelheim International Gmbh Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction
US7148347B2 (en) 2003-04-10 2006-12-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
JP2007501806A (ja) 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
ES2361997T3 (es) 2003-09-22 2011-06-27 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos activos contra el virus de la hepatitis c.
AR045870A1 (es) 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005049065A2 (en) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
CN102911161A (zh) 2004-02-20 2013-02-06 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
RU2006136084A (ru) 2004-03-15 2008-04-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Способ получения микроциклических соединений
AP2006003763A0 (en) 2004-03-30 2006-10-31 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
CA2568008C (en) 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Process for preparing acyclic hcv protease inhibitors
DE102004033312A1 (de) 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
US7671017B2 (en) 2004-07-14 2010-03-02 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
AU2005273619B2 (en) 2004-08-18 2009-05-28 Pfizer Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2006033878A1 (en) 2004-09-17 2006-03-30 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic hcv protease inhibitors
WO2006033851A1 (en) 2004-09-17 2006-03-30 Boehringer Ingelheim International, Gmbh Ring-closing metathesis process in supercritical fluid
SI1802650T1 (sl) 2004-10-01 2012-03-30 Scynexis Inc Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
CN101223161A (zh) 2005-06-24 2008-07-16 健亚生物科技公司 治疗病毒感染的杂芳基衍生物
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007019397A2 (en) 2005-08-05 2007-02-15 Genelabs Technologies, Inc. 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus
MX2008010355A (es) 2006-02-09 2008-10-31 Schering Corp Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
NZ573875A (en) 2006-06-22 2011-11-25 Anadys Pharmaceuticals Inc Pyrro[1,2-b]pyridazinone compounds
KR101143596B1 (ko) 2006-07-07 2012-05-11 길리애드 사이언시즈, 인코포레이티드 신규의 피리다진 화합물 및 이의 용도
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US7981930B2 (en) * 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009005677A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
EA019749B1 (ru) 2007-06-29 2014-06-30 Джилид Сайэнс, Инк. Противовирусные соединения
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
WO2009021121A2 (en) 2007-08-08 2009-02-12 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
CN101918369B (zh) 2007-09-17 2016-02-24 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
RU2490272C2 (ru) 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Макроциклические ингибиторы серинпротеазы
PE20130307A1 (es) 2008-09-16 2013-03-22 Boehringer Ingelheim Int Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv
CA2737376A1 (en) 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
AR073603A1 (es) 2008-09-18 2010-11-17 Ortho Mcneil Janssen Pharm Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
US20110229438A1 (en) 2008-10-09 2011-09-22 Anadys Pharmaceuticals, Inc. Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
MY154683A (en) 2009-07-07 2015-07-15 Boehringer Ingelheim Int Pharmaceutical composition for a hepatitis c viral protease inhibitor
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
CA2813093A1 (en) 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection

Also Published As

Publication number Publication date
NZ598465A (en) 2013-10-25
ZA201201427B (en) 2012-10-31
IL218279A0 (en) 2012-04-30
KR20120106942A (ko) 2012-09-27
AU2010313497B2 (en) 2013-08-01
US20110268700A1 (en) 2011-11-03
JP2013508425A (ja) 2013-03-07
TW201138773A (en) 2011-11-16
BR112012010110A2 (pt) 2019-09-24
EP2493470A1 (en) 2012-09-05
EA201200650A1 (ru) 2012-12-28
MX2012004971A (es) 2012-06-12
AU2010313497A1 (en) 2012-03-22
CN102596201A (zh) 2012-07-18
WO2011053617A1 (en) 2011-05-05
PH12012500827A1 (en) 2013-01-07
CA2779244A1 (en) 2011-05-05
US8822496B2 (en) 2014-09-02

Similar Documents

Publication Publication Date Title
CL2012001082A1 (es) Uso del acido (1r,2s)-1-[[(2s,4r)-4-[8-bromo-7-metoxi-2-[2-(2-metilpropanoilamino)-1,3-tiazol-4-il]quinolin-4-il]oxi-1-[(2s)-2-(ciclopentiloxicarbonilamino)-3,3-dimetilbutanoil]pirrolidin-2-carbonil]amino]-2-etenilciclopropan-1-carboxilico (bi201335), un interferon alfa y ribavirina para tratar la infeccion de hepatitis c viral.
CL2012001230A1 (es) Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c.
ECSP17064986A (es) Compuestos antivirales
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
CO6390076A2 (es) Inhibidores de hcv ns5a
CO6390077A2 (es) Inhibidores de hacv ns5a
EA201892671A1 (ru) Пегилированный свиной интерферон и способы его применения
IL192373A (en) Arginine cyclic peptides and their use in the treatment of fungal infections
CL2012001637A1 (es) Compuestos derivados de bi-(5-fenil-2-(pirrolidin-2-il)-1h-imidazol), con actividad inhibidora de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc), composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c.
CL2007003250A1 (es) Compuestos derivados de isoquinolina, inhibidores del virus de hepatitis c; composicion farmaceutica; y uso para el tratamiento de una infeccion por vhc.
TR201815062T4 (tr) Viral enfeksiyonların tedavisine yönelik pirimidin deriveleri.
EA201001276A1 (ru) Ингибиторы вируса гепатита с
EA200900297A1 (ru) Ингибиторы вируса гепатита с
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
CL2011000716A1 (es) Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
WO2007008657A3 (en) Hepatitis c virus inhibitors
EA201101082A1 (ru) Ингибиторы вируса гепатита с
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
MX2013011411A (es) Tratamiento para infeccion por el virus de hepatitis b solo o en combinacion con el virus de hepatitis delta y enfermedades hepaticas asociadas.
BR112013002729A2 (pt) inibidores de vírus de hepatite c
PL2186830T3 (pl) Interferon alfa 2b zmodyfikowany glikolem polietylenowym, jego wytwarzanie i zastosowanie
IN2014DN10288A (es)
WO2013106689A8 (en) Hcv ns3 protease inhibitors